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Summary: The use of lyophilized blood as a reference material for glycated haemoglobin was investigated with
respect to IFCC criteria for calibrators and control materials. Ninety-two laboratories, using 11 methods, detected
no changes in glycated haemoglobin content when the lyophilizate was stored for one year at 4 °C. Affinity chroma-
tography, HPLC, electrophoresis and immunoassay detected no changes following 18 months storage at -84 and
—20 °C. Samples for HPLC are stable at 4 °C for one year, and 5 years at -20 °C. For the other three methods,
samples are stable for 5 years at 4 °C. At 4 °C, reconstituted samples are stable for 2 days (HPLC) and 7 days
(other three). Lyophilization does not cause matrix effects and inhomogeneity, since mean glycated haemoglobin
and reproducibility for lyophilized samples and whole blood were similar. The coefficient of variation for vial
filling precision was 0.59%. We conclude that lyophilized blood samples can be used as calibrators and control
materials. Their use as calibrators, following assignment of the HbAlc value by HPLC, may contribute, in the
interim, to the standardized interpretation of long term diabetic control.
Introduction
Glycated haemoglobin is a valuable indicator for long-
term diabetic control (1). At present, mean intra-labo-
ratory CVs amount to 5.2% (range: 0.2-28.7%),
whereas inter-laboratory CV is about 20% (24% and
20% at glycated haemoglobin values of 5.0% and
15.8%, respectively) (2, 3). It implies that few
laboratories meet the recommended intra-laboratory
CV of < 5% (4), or the clinically more desirable CV
of < 3.3% (5), and that glycated haemoglobin results
from different laboratories are hardly comparable.
Measurement of different analytes (e. g. glycated hae-
moglobin or HbAic), methodological imperfections
and lack of a primary standard and reference method
contribute to the present dispersion of glycated haemo-
globin results (6, 7). Standardization by the use of
calibrators with assigned values has been proposed
(8). In a recent pilot study, we (9) showed that three-
point calibration reduces intra-laboratory CV from
6.6% to 3.5%, and inter-laboratory CV from 25 to 7%
(at 5.5% glycated haemoglobin and from 15 to 4%
(at 14.1% glycated haemoglobin).
Calibrators for the glycated haemoglobin standardiza-
tion study were prepared by lyophilization of dialysed
and subsequently haemolysed EDTA-blood from non-
diabetic and diabetic volunteers (3). This procedure has
been used for many years for the distribution of quality
assurance samples in an external quality control pro-
gramme in The Netherlands (3). Suitability of the
method for the preparation of reference material and cal-
ibrators according to IFCC recommendations for cali-
brators and control materials (10) was, however, not
tested. In this study we investigated the stability of both
lyophilized and reconstituted material, matrix effects
and the homogeneity of the candidate reference mate-
rial.
Materials and Methods
Samples
Lyophilized samples, stored in vacuum sealed vials, were pre-
pared by the SKZL (the Dutch Foundation for Quality Control
in Hospital Laboratories) according to the previously described
procedure (3).
Stabi l i ty of lyophil ized material
One batch of 630 vials was prepared in July 1991. The vials
contained lyophilized reference material of a single haemolysate
pool with a glycated haemoglobin of 9.8%, as determined
by HPLC (Diamat Bio-Rad, Βίο-Rad Laboratories, Brea, CA,
USA).
Four sets of 120 vials each were immediately stored at 4 °C in the
dark. They were successively distributed to serve in the regular
external quality control programme. Distribution was by post at
ambient temperatures. The participants were unaware of the sim-
ilarity of the material. The 4 sets were analysed 2.5, 6, 9 and 12
months after preparation, respectively.
Immediately after preparation the remaining 150 vials were stored
in 5 sets of 30 vials each at -84, -20, 4, 22, and 37 °C, respec-
tively. Five vials stored at each of the above temperatures were
used for glycated haemoglobin analyses after 0, 3, 6, 9, 12 and
18 months.
Stabi l i ty of reconsti tuted mater ia l
Two sets of 30 vials, containing lyophilized material from EDTA-
blood samples with low (5.5%; HPLC, Diamat Bio-Rad) and high
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(11.3%) glycated haemoglobin, respectively, were prepared. On
days 0 (day of lyophilization-complction), 2, 4, 5, 6 and 7 we
reconstituted 5 samples of each set with water to give final glycated
haemoglobin concentrations equal to those in EDTA-blood. Recon-
stituted samples were stored at 4 °C in the dark. Their glycated
haemoglobin fractions were analysed in one series on day 7; i.e.
after 0, I, 2, 3, 5 and 7 days storage.
Matr ix-effects
EDTA-blood samples were collected from a non-diabetic (glycated
haemoglobin 5.3%; HPLC. Diamat Bio-Rad) and diabetic (11.4%)
volunteer. After division of each sample in two aliquots, one part
was immediately processed to lyophilized samples and the other
stored at 4 °C for 2 days (i. e. until completion of the lyophilization
process). Immediately after lyophilization was completed, glycated
haemoglobin was analysed in both lyophilized material and stored
EDTA-blood samples. Each sample was analysed 10-fold.
Homogenei ty
Homogeneity was tested during the preparation of 1700 vials, each
from haemolysates with low (5.3%; HPLC? Diamat Bio-Rad) and
high (11.4%) glycated haemoglobin. At intervals of 100 vials a
total of 17 vials was taken during the filling procedure. Empty and
filled vials were weighed to determine filling precision. Separate
sets of 10 vials each were randomly selected for single analyses of
glycated haemoglobin. Results were compared with 10-fold analy-
ses in original haemolysates in the same series. Original haemoly-
sates had been stored at 4 °C for 2 days (i. e. until completion of
the lyophilization process).
Analyt ica l methods
For the establishment of stability, matrix effects and homogeneity we
used 4 commercially available glycated haemoglobin tests, accord-
ing to the manufacturers' instructions. The tests were: Pierce affinity
chromatography (Pierce, Glycotest II, Pierce, Rockford, IL, USA);
Bio-Rad Diamat HPLC (Bio-Rad Diamat, Bio Rad Laboratories,
Brea, CA, USA); Beckman electrophoresis (Beckman, Diatrac,
Beckman Instruments, Brea, CA, USA); and the DAKO immuno-
chemical method (ITK, HbA,c, DAKO, Cambridge, UK).
For stability studies in the external quality control programme, the
participants also used the following commercially available meth-
ods, all but one according to the manufacturers' instructions: modi-
fied Pierce affinity chromatography (modification: 10ml instead
of 5 ml elution wash buffer; Glycotest II, Pierce, Rockford, 1L,
USA); Isolab affinity chromatography (Glyc-Affin; Isolab, Akron,
OH, USA); HPLC Bio Rad Modular (Bio-Rad Laboratories and
designed for HbAlc with Bio-Rad TSK column, Brea, CA, USA);
Pharmacia HPLC (various HPLC systems equipment with Phar-
macia Mono-S HR 5/5 columns; Pharmacia-LKB Technology, Up-
psala, Sweden); Disposable ion exchange columns (HbA,c test;
Bio-Rad Laboratories, Brea, CA, USA); Corning electrophoresis
(Corning Medical Ltd, Halstead, UK); and Sebia electrophoresis
(Hydrated glycosylated haemoglobins, Sebia, Issy-les-Mouli-
neaux, France).
Statistics
Statistically significant differences between mean glycated haemo-
globin values and SDs were determined with Student's t- and F-
tests (9), respectively, at p < 0.05. We used two-way ANOVA to
compare the combined effects of different laboratories and at dif-
ferent times (tab. 1). Repeated measurements were used to evaluate
the glycated haemoglobin changes during storage-experiments
shown in tables 2 and 3 (12).
Results
Stability of lyophilized material
Table 1 shows mean glycated haemoglobin fractions and
mterlaboratory SDs, as determined by 92 laboratories
using 11 different methods. Lyophilized samples were
analysed after 2.5, 6, 9 and 12 months storage at 4 °C.
Some methods were performed by only a few laborato-
ries. Their results should therefore be interpreted with
caution. Except for results for the sample that was stored
for 9 months and analysed by affinity chromatography
(Pierc&Miedema), none of the methods showed signifi-
cant changes in glycated haemoglobin fractions during
12 months storage (according to ANOVA). The disper-
sion of glycated haemoglobin fractions measured in dif-
ferent laboratories using the same method (expressed as
the Intel-laboratory SD) was invariable.
Table 2 shows selected results of the experiment with
lyophilized samples that had been stored for various
months at various temperatures. Immediately after lyo-
philization, the fraction of glycated haemoglobin in the
batch was determined with 4 methods (affinity chroma-
tography, HPLC, electrophoresis, immunoassay) in a
single laboratory. Vials were stored at —84, —20, 4, 22
and 37 °C, respectively. Glycated haemoglobin was re-
analysed after storage for 3, 6, 9, 12 and 18 months.
Table 2 shows the initial glycated haemoglobin fractions
and the fractions found after 18 months storage. Gly-
cated haemoglobin fractions determined by HPLC in
samples that had been stored at —84 and —20 °C were
not different from initial glycated haemoglobin fraction.
The values for glycated haemoglobin in samples stored
at 4, 22 and 37 0C were, however, lower than the initial
glycated haemoglobin and lower than the value for gly-
cated haemoglobin in the sample stored at -84 °C. Fig-
ure 1 shows HPLC profiles of lyophilized samples
stored for 18 months at -84 (a) and 37 °C (b), respec-
tively. The sample stored at 37 °C contained an addi-
tional peak, that influenced both HbAlc and HbA0 integ-
ration. Glycated haemoglobin values determined by
electrophoresis and affinity chromatography were lower
in all stored samples, compared with initial values. No
significant differences were observed between samples
stored at -84, -20, 4 and 22 °C. Compared with the
sample that was stored at —84 °C, the sample stored at
37 °C showed a higher glycated haemoglobin fraction in
affinity chromatography, and a lower glycated haemo-
globin in electrophoresis. As determined by immuno-
assay, the glycated haemoglobin of all stored samples
was higher than the initial glycated haemoglobin, except
in the case of the sample stored at -84°C, which
showed no difference. Results of 3, 6, 9 and 12 months
storage are not shown. For storage at 37 °C the first de-
viating results (according to repeated measurements)
were observed at 3 months (HPLC; lower glycated hae-
moglobin), 9 months (affinity chromatography (higher
glycated haemoglobin) and 12 months (electrophoresis;
lower glycated haemoglobin). At 22 °C, deviating re-
sults were only observed with HPLC at 6 months (lower
glycated haemoglobin).
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Stability of reconstituted material
Lyophilized samples were reconstituted on days 0, 2, 4,
5, 6 and 7, stored in the interim at 4 °C, and analysed on
day 7 in one series. Table 3 shows glycated haemoglobin
results for the freshly reconstituted sample (storage time
0 days), together with results from samples that were
reconstituted 1, 2, 3, 5 and 7 days before analysis,
respectively. The data were obtained with 4 methods and
applied to samples that contained low and high glycated
haemoglobin fractions, respectively. Repeated measure-
ments with affinity chromatography, electrophoresis and
immunoassay revealed no changes in the glycated hae-
moglobin values. When measurements were performed
with HPLC, glycated haemoglobin was found to be de-
creased in samples that had been stored for 3 days or
longer (low glycated haemoglobin) and 5 days or longer
(high glycated haemoglobin).
Matrix effects
To investigate possible matrix effects introduced by the
lyophilization procedure, glycated haemoglobin frac-
tions were determined in a whole blood sample that had
been stored for 2 days at 4 °C, and in the same sample
that been lyophilized in that period. Results of analyses
of samples with low and high glycated haemoglobin
fractions by 4 methods, are shown in table 4. Lyophiliza-
Tab. 1 Mean ± SD giycated haemoglobin fractions3 per method as determined by 92 laboratories
a lyophilized sample stored at 4 °C for 2.5, 6, 9 and 12 months.
in
Method No. of
laboratories
Storage at 4 °C
2.5 months 6 months 9 months 12 months
Affinity Chromatography
Pierce-Miedema
Pierce
Isolab
HPLC
Bio Rad Diamat
Bio Rad Modular
Pharmacia
Electrophoresis
Beckman
Corning
Sebia
Disposable ion exchange
Bio Rad HbAlc
Immuno Assay
DAKO
34
3
1
7
13
7
15
3
1
1
8.4 ± 0.7
10.0 ± 0.2
10.8
10.1 ± 0.6
9.8 ± 0.6
9.0 ± 0.6
9.2 ± 1.3
11.1 ±0.7
12.0
9.3 ± 0.8
7.4
8.2 ± 0.8
10.7 ± 0.8
10.0
9.7 ± 0.3
9.9 ± 0.4
9.3 ± 0.8
9.5 ± 1.1
10.3 ±0.9
11.7
8.9 ± 0.4
7.2
8.0b ± 0.6
10.2 ±0.5
11.6
10.0 ±0.3
9.7 ±0.6
9.0 ± 1.1
9.3 ± 1.2
10.8 ±0.8
11.9
10.0 ±0.6
7.0
8.2 ± 0.8
9.7 ± 0.3
11.2
9.9 ± 0.7
9.6 ± 0.4
9.2 ± 1.1
9.2 ±0.1
11.2 ±0.7
11.9
9.9 ± 0.5
7.4
a
 Mean ± inter-laboratory SD
b
 Significantly different from mean glycated haemoglobin after 2.5 months (p < 0.05).
Tab. 2 Mean ± SD glycated haemoglobin fractions8 as determined by 4 methods in a lyophilized
sample stored at various temperatures during 18 months.
Storage temperature
in°C
Affinity chromatography
Pierce
HPLC
Bio Rad - Diamat
Electrophoresis
Beckman
Immuno assay
DAKO
Initial fractions of glycated haemoglobin0
9.70 ±0.18 9.80 ±0.03 10.32 ±0.47 7.27 ± 0.27
-84
-20
4
22
37
After storage
8.42 ±0.20
8.53 ±0.17
8.28 ± 0.27
8.27 ±0.23
9.35C ± 0.38
9.81 ±0.03
9.82 ±0.03
9.48C ± 0.05
8.83C ± 0.04
8.56c±0.17d
9.07 ±0.53
9.31 ±0.58
9.08 ±0.43
9.52 ±0.73
8.03C ± 0.66
8.23 ± 0.23
8.06 ± 0.23
8.04 ±0.1 8
8.31 ±0.26
8.09 ± 0.22
Λ
 Mean ± SD for 5 assays c Mean significantly different from mean of sample stored at
b
 Glycated haemoglobin fraction as determined in the sample be- -84 °C (p < 0.05).
fore storage. d SD significantly different from SD of sample stored at -84 °C
(p < 0.05).
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tion did not affect the glycated' haemoglobin results
as obtained by affinity chromatography, electrophoresis
and immunoassay. Analyses by HPLC showed small,
but significant, glycated haemoglobin increase in the
samples containing low (absolute increase 0.14%) and
high (absolute increase 0.17%) concentrations of gly-
cated haemoglobin. Figure 2 shows HPLC and electro-
phoretic profiles of whole blood and lyophilized blood,
using the sample containing a high concentration of
glycated haemoglobin. Lyophilization caused a small
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peak (retention time 1.2 min) to disappear from the
HPLC-chromatogram. No other differences were de-
tected.
Homogeneity
Mean filling weight amounted to 123.9 mg with a CV
of 0.59%. The reproducibility of assays in whole blood
and lyophilized blood is shown in table 4. Except for
the analysis of the low glycated haemoglobin concentra-
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Fig. 1 Glycated haemoglobin profiles of iyophilized samples, as
determined by HPLC (Diamat, Bio-Rad) after 18 months storage
at-84°C(a)and37°C(b).
Peaks: 1 = HbAic; 2 = HbAo, 3 = Decomposition product.
Tab. 3 Mean ± SD glycated haemoglobin fractions3 as determined by 4 methods in a reconstituted
sample stored at 4 °C during 0-7 days.
Storage
time
in days
0
1
2
3
5
7
Affinity chromatography
Pierce
Glycated haemoglobin
low high
3.86 ±0.1 5 11. 59 ±0.37
3.81 ±0.12 11.52 ±0.23
3.83 ±0.24 11. 48 ±0.32
3.88 ±0.10 11.53 ±0.17
3.87 ±0.1 7 11. 62 ±0.43
3.84 ±0.17 11.55 ±0.35
HPLC
Bio Rad, Diamat
Glycated haemoglobin
low high
5.50 ±0.05 11.27 ±0.08
5.51 ±0.04 11.25 ±0.09
5.46 ±0.07 11.32 ±0.07
5.21b±0.11 11.22 ±0.12
4.94b±0.12c 10.98b±O.I5
4.82b± 0.20C 10.28b± 0.24
Electrophoresis
Beckman
Glycated haemoglobin
low high
4.61 ± 0.67 11.20 ± 0.33
4.37 ±0.47 11.03 ±0.78
4.43 ±0.61 11. 15 ±0.63
4.71 ±0.38 11. 29 ±0.48
4.68 ±0.71 11.38 ±0.73
4.52 ±0.58 11. 16 ±0.63
Immuno assay
DAKO
Glycated haemoglobin
low high
3.47 ±0.06 11. 72 ±0.30
3.44 ±0.09 11.71 ±0.26
3.46 ±0.05 1 1.75 ±0.25
3.48 ±0.08 11. 68 ±0.17
3.43 ±0.03 11. 72 ±0.41
3.43 ±0.09 11. 73 ±0.32
a
 Mean ± SD for 5 assays.
b
 Mean significant different (p < 0.05) from mean of freshly re-
constituted sample (day 0).
c
 SD significantly different (p < 0.05) from SD of freshly reconsti-
tuted sample (day 0).
Tab. 4 Mean ± SD glycated haemoglobin fractions in whole blood and lyophilized samples with low
and high glycated haemoglobin fractions, as determined by 4 methods.
Method Low glycated haemoglobin High glycated haemoglobin
Affinity chromatography (Pierce)
HPLC (Bio-Rad, Diamat)
Electrophoresis (Beckman)
Immuno assay (DAKO)
Whole blood
3.77 ±0.17
5.28 ± 0.04
4.24 ±0.31
3.35 ± 0;08
After lyophilization
3.81 ±0.14
5.42a ± 0.04
4.32 ±0.65b
3.33 ±0.07
Whole blood
11.61 ±0.24
11. 37 ±0.06
1 0.97 ±0.49
11. 63 ±0.27
After lyophilization
11.74 ±0.30
11.54 ±0.09
10.76 ±0.38
11.66 ±0.24
a
 Mean after lyophilization significantly different from mean of
whole blood (p < 0.05).
b
 SD after lyophilization significant different from SD of whole
blood (p < 0.05).
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tion by electrophoresis, none of the intra-sample SDs in
the lyophilized haemolysates were found to be signifi-
cantly different from those of the corresponding whole
blood.
Discussion
The IFCC recommendations for calibrators and control
materials refer to stability, matrix effects and homo-
geneity as important quality criteria (10, 13). We tested
these for the glycated haemoglobin reference material
that is currently used in the SKZL external quality as-
sessment programme.
We used two approaches to test the stability of the lyo-
philized material. In a multi-centre study 92 laboratories,
using 11 methods, detected no differences in the gly-
cated haemoglobin value over a period of one year. The
second approach to test glycated haemoglobin stability
was based on the assumption that (bio)chemical pro-
cesses proceed 2—3 times faster with every 10 °C tem-
perature increase (14). A reference material that proves
stable for n months at χ °C is expected to be stable for
4n months at (x-20) °C. Samples stored at various tem-
peratures were stable at the conventional refrigerator
temperature of 4 °C for at least 5 years when analysed
a
by affinity chromatography, electrophoresis and
immunoassay and for 1 year for HPLC analysis. The
underlying cause of decreased stability with HPLC is the
appearance of an extra peak that elutes between HbAic
and HbA0, and thereby affects integration properties
(fig. 1). Formation of an interfering component has pre-
viously been noted and is often referred to as formation
of HbA3 (16). From both multi-centre and storage
studies we conclude that the lyophilized material is
essentially stable. Stability of the reconstituted material
was investigated by storage at 4 °C during 0-7 days.
These storage-tests of the reconstituted material at
4 °C revealed 2 days stability for HPLC and 7 days
for the other techniques. Again, HbA3 formation limits
the apparent stability in HPLC. Lyophilization and
addition of cryoprotectants change the biological mat-
rix and may thereby cause deviant glycated haemoglo-
bin behaviour, compared with whole blood. Results
show that lyophilization does not affect the concentra-
tion of glycated haemoglobin as determined by affinity
chromatography, HPLC, electrophoresis and immuno-
assay. The comparable precision of glycated haemoglo-
bin assays of lyophilized samples and whole blood
indicates that the homogeneity of the lyophilized mate-
rial is acceptable.
1o
6
Retention time [min]
Fig. 2 Glycated haemoglobin profiles as determined by HPLC
(Diamat, Βίο-Rad; top-panels) and electrophoresis (Beckman; bot-
tom panels) for whole blood (a) and after lyophilization (b). S is
the application point (a).
Peaks: I = HbAlc; 2 = HbA«.
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Standardization of glycated haemtfglobin assays is a pre-
requisite for a standardized interpretation of long term
diabetic control. The need for standardized interpretation
has been shown in the DCCT study (17). Since a basic
solution is not to be expected before the end of this
century, standardization by calibration (8, 9) is proposed
as a pragmatic, interim, approach. This requires the use
of a reliable calibrator, whose preparation is complicated
by the brittle structure of haemoglobin. We conclude
that the lyophilized material used in the SKZL external
quality programme meets IFCC-criteria for stability,
homogeneity and matrix effects. The samples can be
used both as calibrators and control materials. Its accep-
tance for calibration requires reliable assignment of a
glycated haemoglobin value. Assignment of an HbAlc
value on the basis of an absolute HbAjc method that
uses a primary standard mixture of purified HbAic and
HbA0 would be ideal. However, neither pure HbAlc nor
an absolute method are available (15). Assignment of a
glycated haemoglobin value on the· basis of the HPLC
method that was used in the DCCT study seems a rea-
sonable iterim solution for achieving a standardized in-
terpretation of long term diabetic control.
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Evaluation of a Second-Generation Thyrotropin Automated Immunoassay
Laurent Boon-Falleur and Philippe De Nayer
Laboratoire de Medecine Nucleaire, Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain,
Bruxelles, Belgium
Summary: We evaluated the analytical performance of the Vista automated immunoassay system for human thyro-
tropin determination. The operating characteristics as well as the analytical performance were assessed. The Vista
human thyrotropin immunoassay showed a minimal detection limit of 0.08 mU/1 and a functional sensitivity of
0.12 mU/1. The system meets the criteria for second-generation human thyrotropin assays.
Introduction
Immunometric assays for thyrotropin have replaced the
less sensitive thyrotropin radioimmunoassays. Immuno-
metric assays have lower detection limits and possibly a
faster turnaround time. Second and third-generation hu-
man thyrotropin assays (20% inter-assay CV at 0.1 to
0.2 mU/1 and 0.01 to 0.02 mU/1) are becoming available
on automated immunoassay analysers (1, 2). The transi-
tion between radiometric techniques and fluorometric or
chemiluminescent techniques requires careful assess-
ment of the performance of the newer kits. Indeed, the
use of a non-isotopic signal is not, per se, a guarantee
of quality.
This report describes the evaluation of an automated im-
munoenzymometric assay (Vista hTSH, Syva) for detec-
tion of human thyrotropin. This kit is compared with an
IRMA method (Riabead II, ABBOTT).
Materials and Methods
Sera and serum pools
Samples were collected in dry tubes, separated, and the serum fro-
zen at —20 °C. For intra- and inter-assay purposes, routine samples
were pooled according to their human thyrotropin values and ali-
quoted before freezing at -20 °C.
Controls
We used human serum pools containing different concentrations of
human thyrotropin to evaluate the intra- and inter-assay precision
of the system. Routine sera were used to correlate the results of
this system with the Abbott method.
Method used for comparison
Immunoradiometric assay (IRMA): Riabead II (Abbott). This assay
shows a 20% inter-assay CV at 0.1 mU/1.
Method under evaluation
The Vista assay is a two-step sandwich method based on two mo-
noclonal antibodies. The capture antibody, specific for the intact
human thyrotropin molecule, is coupled to chromium dioxide para-
magnetic particles (CrO2) (3). This solid phase system presents a
very large surface area, compared with more classical solid-phase
techniques such as coated tubes, polystyrene beads or microtitre
plates. The CrU2 particle is separated by a magnetic procedure. The
second antibody, specific for the β subunit of human thyrotropin
molecule, is conjugated to alkaline phosphatase.
VISTA analyser
The Vista immunoassay system is a benchtop multitest analyser
that provides a large panel of methods (max. 15 in the same run).
The system can handle 50 different samples and perform a maxi-
mum of 100 measurements in a run.
This analyser provides on-board refrigerated reagent storage, elimi-
nating the need for daily manipulations of reagents before each
run. Calibration curves are kept in memory for 30 days (human
thyrotropin assay).
The sample (100 μΐ) is dispensed by the system. The CrO2 particles
and the second antibody are then added and incubated for a period
of 30 min at 37 °C. The particles are washed and 4-methyl-umbil-
liferyl phosphate is added to produce the fluorescent signal.
Calibrat ion
The human thyrotropin assay was calibrated using the calibrators
provided with the system (5 point calibration curve). The calibra-
tion curve for a reagent lot is stable for 30 days. Two calibration
curves for two different reagent lots can coexist in memory. Before
each run, the system automatically fits its calibration curve(s) for
the different assays by a two point normalization of the curve(s),
using a quinine sulphate solution to standardize the fluorometer.
Results
Operating characteristics
During our testing period, we found that a mean of 30
minutes was enough to start the system every morning,
including the time for pipetting samples into the ana-
lyser cups. The FT4 assay was also evaluated during the
same runs (unpublished data). Each run was complete
after 140 minutes, but all results are available after 120
minutes. The remaining time is consumed by an exten-
sive washing procedure for the reaction cuvettes, prior
to their disposal (according to United States legal con-
straints). Dining the run, the analyser is truly 'walk-
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away1 in routine use. This time schedule easily allows
the performance of three different runs in a day, i. e. 150
samples can be assayed and a maximum of 300 results
can be obtained.
Intra-assay reproducibi l i ty
Ten pools covering the entire range of the human thyro-
tropin assay were aliquoted and measured 10 times in
the same run. Table 1 summarizes the values obtained.
A CV below 20% is obtained for human thyrotropin
values above 0.05 mU/1 (mean value of 0.05 mU/1: CV
of 19.2%).
Inter-assay reproducibi l i ty
Ten pools, covering the entire range of the human thyro-
tropin assay were aliquoted, frozen at -20 °C and as-
sayed in 10 different runs on different days. Table 1
presents the collected data. A CV below 20% is obtained
for human thyrotropin values estimated at around 0.12
mU/1. This is commonly taken to represent the func-
tional sensitivity of an assay (2).
Analy t ica l sensitivity
To determine the analytical sensitivity limit of the assay,
the zero standard was assayed ten times in the same run.
The mean fluorescence level (measured in Fluorescence
Units, FU) + 2 SD (Standard Deviation: 6.2 FU) was
522 FU. This is lower than any fluorescence level ob-
served for any sample assayed.
The concentration mean for standard 0 derived from the
calibration curve is negative (—0.012 mU/1; SD
= 0.006 mU/1).
Minimal detection l imit
The minimal detection limit is commonly evaluated by
a dilution test. We selected single samples and per-
Tab. 1 Intra- and inter-assay reproducibility.
The mean thyrotropin value obtained for ten replicates of the sera
is tabulated for intra- and inter-assay against the CV obtained for
those values. The precision cutoff is fixed at 20% CV. For intra-
assay, this precision is obtained for thyrotropin values > = 0.05
mU/1. For inter-assay, this precision is obtained for thyrotropin val-
ues estimated above 0.12 mU/1.
Intra-assay Inter-assay
Mean thyrotropin
(mU/1)
0.01
0.05
0.14
0.25
0.45
0.92
1.80
2.89
12.65
53.81
CV
(%)
59.8
19.2
5.5
5.5
2.2
5.1
2.5
3.4
2.6
2.6
Mean thyrotropin
(mU/1)
0.01
0.04
0.05
0.19
0.36
0.88
1.64
2.34
6.74
36.80
CV
(%)
97.6
24.9
26.5
13.4
5.4
5.3
7.0
15.2
8.0
8.7
1.20 -r
0.60
υ
o0.40
I
>
£
0.20 --
ΪΓ--0
0.5 1 1.5
Thyrotropin [mU/l]
2.5
Fig. 1 Minimal detection limit.
u dUUtion- ™e Cutoff is fixed at the *^οΡ'η concentration for
er e,™ f , i ainst the recov- which the calculated recovery shows a 20V, variation from the ini-
ery, expressed m fract.on of the nutm! value after correction for tial value. A cutoff value of 0.08 mU/1 is obtained.
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formed serial dilutions with the diluent provided with
the kit. The dilutions were assayed in a single run for
each sample. The cut-off was fixed at the calculated
value (corrected for dilution) showing a 20% variation
from the initial value. Figure 1 presents the curves of
the obtained values. A minimal detection limit of 0.08
mU/1 was obtained by this method.
Correlation with Abbott method
Samples (n = 118) were assayed in the two methods
(Abbott (x) and Vista (y)). Over the entire range of hu-
man thyrotropin concentrations (from 0 to 40.6 mU/1),
there was a good agreement between the two methods.
(y = 0.93 χ + 0.03 r = 0.99)
For human thyrotropin concentrations less than 1 mU/1
(fig. 2), the Vista method gave slightly lower values than
the Abbott assay.
(y = 0.90 χ + 0 r = 0.96)
Interference of human anti-mouse
immunoglobul in antibodies
Three sera from a single patient treated with OKT3 (mu-
rine monoclonal antibody) were selected for this study.
This patient developed human anti-mouse immunoglob-
ulin antibodies after treatment (4).
Table 2 compares data from sera with and without addi-
tion of normal mouse serum, measured with the Abbott
RIA method and the Vista assay. The Vista reagents
clearly eliminate the interference which is seen for the
Abbott method in the absence of normal mouse serum.
Discussion
Over the last ten years, the introduction of immuno-
metric methods and non-radioisotopic labels have re-
sulted in significant progress in the measurement of thy-
rotropin. The gain in sensitivity has led to a generational
classification based on the minimal concentration yield-
ing a between^-assay CV of 20% (2). The latter figure is
close to the minimum detection limit interpolated from
the precision^dose profile at a CV of 22%, as proposed
by McConway et al. in a study of ten manual IRMAs or
non-isotopic immunometric assays for human thyrotro-
pin (5).
The routine use of non-isotopic labels in automated as-
say systems is growing in clinical laboratories. Although
second and third-generation sensitivity (inter-assay CV
of 20% respectively at 0.1-0.2 mU/1 and 0.01-0.02
mU/1) methods are available for manual operation, the
transfer of this methodology to automated versions has
yet to be validated.
1.20 τ
0.00 V
0.00 0.50
Thyrotropin (Abbott) [mU/1]
1.00
Fig. 2 Correlation between Syva Vista and Abbott Riabead II as-
say.
Patient sera were assayed by the Vista method and correlated with
values obtained by the Abbott Riabead II method. The sera were
selected for thyrotropin values < = 1 mU/I with the Vista method,
(y = 0.90 χ + 0, r = 0.96, η = 44)
Tab. 2 Interference of human anti-mouse immunoglobulins anti-
bodies.
The sera were assayed by the Vista method and by the Abbott
Riabead II method, with and without addition of 10 μΐ of normal
mouse serum.
Serum Thyrotropin (mU/1)
Abbott Abbott
without with
normal mouse serum
Vista Vista
without with
normal mouse serum
A1
B2
C2
1.9
33.3
46.0
1.1
1.7
1.1
1.15
0.99
1.10
1.05
a
1.03
1
 before treatment
2
 after treatment with OKT3 (murine monoclonal antibody)
a
 not enough serum to be assayed
A recent report indicates that for automated assays,
third-generation functional sensitivity is not consistently
reached in clinical practice despite the claim of manu-
facturers (6). These authors and others (7) also point to
the need for improving the robustness of assays — even
second-generation assays — to ensure their performance
in clinical laboratory routine.
The results obtained in the present study with the VISTA
immunoanalyser indicate that the performance of the
thyrotropin assay corresponds to second-generation sen-
sitivity. This IMA, based on a fluorescent label, appears
to be equivalent to the Abbott IRMA technique used as
the comparison method.
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Summary: The introduction of a new and automated CA 15-3 immunoassay (IMx Abbott) prompted us to compare
the analytical performance of this new test with established tests from CIS ELSA, Sorin, and Boehringer Mannheim
in a multicentre study.
CA 15-3 measurements in blood samples of breast tumour patients, comparison of intra- and inter-assay variation,
dilution linearity, and lower limit of detection are described. The study showed improved precision for the automated
over the manual test systems (intra-assay variation: IMx < 5%, CIS ELSA 4-9%, ES 300 < 3% and ETf Sorin
> 10%; inter-assay variation: IMx < 8%, CIS ELSA < 19%, ES 300 < 9% and ΕΤΙ Sorin < 27%).
Results on patients' samples (n = 101 to 184) showed highly comparable results; IMx vs CIS ELSA site I:
r = 0.950; IMx vs CIS ELSA site 2: r = 0.998; IMx vs ES 300: r = 0.980; IMx vs ΕΤΙ Sorin: r = 0.931. Slopes of
regression lines varied from 0.666 for IMx vs ΕΤΙ Sorin to 0.988 for IMx vs CIS ELSA (site 1, where heparin
plasma was used instead of serum as recommended by the manufacturer). Slopes and correlation coefficients were
found to be only slightly dependent on assay ranges analysed by statistical procedures applied.
Despite good correlations between methods, it is recommended that samples collected in the follow-up of disease
and at higher CA 15-3 concentrations are analysed by the same test; a changeover to another test is not encouraged.
Introduction
CA 15-3, a breast-cancer-associated antigen, is found in
the serum of patients with benign lesions and carcinoma
of the breast. The antigen is a high-molecular-mass gly-
coprotein (a MUC1 gene product) belonging to the fam-
ily of polymorphic epithelial mucins (1) and is defined
by epitopes on the CA 15-3 molecule detected by two
different monoclonal antibodies, 115D8 and DF3,
respectively (2, 3).
In most currently used assays for CA 15-3 in serum, the
antibody 115D8 is used as the catcher antibody, while
the DF3 antibody serves as tracer molecule.
CA 15-3 assay values are frequently elevated in patients
with breast cancer (4). It was concluded that the CA
15-3 assay may be of clinical value for monitoring the
response of patients undergoing therapy. Increasing and
decreasing values correlated well with disease pro-
gression and regression, respectively (5). Additional
published data suggested that, in patients at risk for
breast cancer recurrence after primary therapy, increas-
ing CA 15-3 values may indeed be indicative of recur-
rent disease long before it can be detected clinically (5).
CA 15-3 levels appear to be independent of primary tu-
mour histology. Patients with primary breast cancer may
exhibit elevated serum CA 15-3 concentrations, but less
frequently than do patients with melastatic disease. In
the latter situation, elevations of CA 15-3 scrum levels
are correlated with tumour burden and stage.
CA 15-3 is not tumour-specific and the antigen can
be detected by monoclonal antibodies in normal and
in malignant epithelial tissues. Therefore, increased
serum levels can be associated with diseases other
than breast carcinoma (6). Other non-mammary malig-
nancies in which elevated CA 15-3 assay values
have been reported include lung, colon, pancreatic,
primary liver, ovarian, cervical, and endometrial carci-
noma (6).
CA 15-3 assay values are elevated in some normal in-
dividuals, so that this assay is not to be recommended
as a screening procedure for cancer in the general pop-
ulation.
It was the dual purpose of this multicentre study,
(i) to evaluate the analytical performance of the recently
introduced CA 15-3 immunoassay adapted to the Abbott
IMx immunoanalyscr and
(ii) to compare the results with those from the test sys-
tems in use in the respective laboratories (Boehringer
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ES 300, CIS ELSA, and ΕΤΙ Sorin). In addition, com-
mercially available quality-control sera were compared.
Dilution experiments to test the analytical linearity of
the test systems were also included.
Materials and Methods
Methods and reagents
plasma were obtained from
patients. Samples were stored, either at 4 °C to 8 °C for up to 8
days (site 1) or at -20 °C until assayed (sites 2, 3, and 4).
Tab. 1 Analytical performance characteristics, manufacturers' claims
Abbott BMC ΕΤΙ Sorin CIS ELSA
Methodology
Antibody combination3
Assay time
Calibrators (103 U/l)
Kit controls (103 U/l)
Sensitivity(103U/l)
Cut-off (103U/l)b
Sample volume (μΐ)
Automation
Stored curve
Sample predilution
Sample pipetting
Reagent preparation
Off-line incubation
Sample replicates
IMx (MEIA)
115D8/DF3
48 minutes
0/15/60/120/180/250
35/150
<0.2
28
150
yes
yes
no
yes
no
no
1
ES 300 (ELISA)
115D8/DF3
3 hours
0/22/43/101/201
2/93
0.9
26
170
yes
yes
no
yes
yes
no
1
Streptavidin-biotin
(ELISA)
115D8/DF3
> 3.5 hours
0/10/25/50/100/300
18
1
21
25
no
no
yes
yes
yes
yes
2
IRMA coated
115D8/DF3
2 to 2.5 hours
tubes
0/15/40/80/140/240
30
0.2
30
20
no
no
yes
yes
yes
yes
2
a
 Catcher/tracer monoclonal antibody
b
 Abbott: 95.7% of 648 healthy female subjects had CA 15-3 assay
values at or below 28 Χ 103 U/l
Boehringer Mannheim: 95% of 245 healthy subjects with CA 15-
3 values between 0-22 X 103 U/l, 99% below 30 Χ 103 U/l
ΕΤΙ Sorin: The observed range for the CA 15-3 concentration in
100 normal sera and normal plasma was 13.0 ± 8 (mean ± SD)
X 103 U/l
CIS ELSA: In 186 women unaffected by any benign or malignant
pathology, 98.6% of the values were below 30 Χ 103 U/l
P 1600
* 1200
J 80°
400
0
~ 1800
2 3 4 5
Dilution steps
1600
3 4 5
Dilution steps
6 7
2 3 4 5
Dilution steps
Fig. 1 Dilution linearity testing according to the manufacturers' instructions using two patient
specimens per test under investigation.
High starting concentration
-D- IMx target -B- IMx analysed
-D- ES 300 target -D- ES 300 analysed
-D- CIS target -o- CIS analysed
-D- Sorin target -D- Sorin analysed
BMC = Boehringer Mannheim Corporation
3 4 5
Dilution steps
6 7
Low starting concentration
-O- IMx target > ->- IMx analysed
-O- ES 300 target -*- ES 300 analysed
-O- CIS target -*- CIS analysed
-O- Sorin target ->- Sorin analysed
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To analyse CA 15-3, all participating laboratories used the I MX CA
15-3 microparticle enzyme immunoassay (ME1A, lot No. 90191F9)
from Abbott AG, Diagnostics Division, Cham, Switzerland. This
assay uses monoclonal antibody 115D8-coated microparticles and
monoclonal antibody DF3 conjugated to alkaline phosphatase, and
is based on IMx MELA technology (7). Results are based on a
stored six-point calibration curve. The IMx assay utilizes a four-
parameter logistic curve fit (4PL Analysis) to generate a calibration
curve. Assay values are expressed as units per litre (U/l), or 103
U/l and are related to a reference preparation maintained by Abbott.
There is no internationally recognized standard available at this
time. Test performances are listed in table 1.
Two of the four participating sites (sites 1 and 2) compared IMx
results with those generated with the ELSA CA 15-3 test (lot No.
231 A) from CIS Biolnternational, Gif-Sur-Yvette, France. This im-
munoradiometric assay is based on a solid-phase sandwich tech-
nique, which also uses the two monoclonal antibodies 115D8 and
DF3 described above. The first antibody is coated onto the ELSA
solid-phase, the second is radiolabelled with I251 and used as a
tracer. Point-to-point linear interpolation is used to generate the
standard curve (8). Predilution of the samples (1/50) with assay
buffer is required prior to assay.
At site 3, IMx assay results were compared with those generated
by the Enzymun Test CA 15-3 on the ES 300 from Boehringer
Mannheim, Rotkreuz, Switzerland (reagent lot No. 64593801).
This test system consists of a two-step ELI S A using streptavidin-
biotin technology (9). Results are read from a five-point calibra-
tion curve.
Site 4 compared Abbott IMx values with those established with
the manual assay ETI-CA-15-3 K from Sorin Biomedica, Antony,
France (lot No. 9150010 A and B). Like the other assays under
investigation, it utilizes the monoclonal antibodies 115D8 and DF3
and is a one-step sandwich immunoenzymatic assay using streptav-
idin-biotin technology. The capture antibody (l 15D8) is conjugated
to biotin while the other (DF3) is labelled with horseradish peroxi-
dase. Results are based on a five-point calibration curve and point-
to-point linear interpolation (10).
The following commercially available control materials were used:
Lyphochek Tumour Marker Control Levels 1 and 2 (BIO-RAD
Laboratories AG, Glattbrugg, Switzerland, lot No. 57900 and
64200) and BioRef (BioRef GmbH, Mombris, Germany) 1 and 2
(lot No. 920161).
Imprecision
In order to assess the intra-assay imprecision, the internal control
solutions from the respective CA 15-3 test systems, Lyphochek
tumour marker control levels 1 and 2, the tumour marker control
BioRef levels 1 and 2, and a pool of human serum were each
measured in 20-^fold replicates.
In order to calculate inter+assay imprecision, duplicate determin-
ations with IMx and CIS controls as well as Lyphochek levels 1
and 2 or BioRef 1 and 2 were carried out on 10 working days.
Lower limit of detection
The potential lower limit of detection was determined according to
"Clinical Laboratory Improvement Amendment" CLIA (11). Lower
limit of detection is defined as the lowest concentration of analyte
that can be distinguished from zero with a 95% confidence limit
of detection. Following these rules, the zero-calibrators of the indi-
vidual tests were analysed in replicates of 10 on two different days.
Dilut ion linearity
Each laboratory carried out linearity tests. Specimens containing
out-of-range elevated levels of CA 15-3 were diluted according
to the manufacturer's instructions to provide four or more diluted
samples reading in the calibration curve range. All dilutions were
run in duplicate in all tests. Linear regression analysis for each of
the chosen specimens was performed and the end concentrations
calculated (target values', cf. fig. 1).
Qual i ty control of ana ly t i ca l procedures
The test performance was checked by comparing the assigned val-
ues of at least three commercial quality control sera with the values
obtained for these sera in each run.
Sample comparison
Patient samples were run in duplicate in the manual methods and
singly in the automated methods, and results compared. In each
laboratory the method in use was compared with the IMx method.
Statistical analysis of results was performed by the method of Pass-
ing & Bablok (\2).
Results
Imprecis ion
Intra-assay variation (tab. 2):
Pools of locally available sera containing average CA
15-3 concentrations of 10 to 20 Χ 103 U/l and IMx con-
trol sera showed coefficients of variation (CVs) well be-
low 5% with the IMx method.
In comparison, the CIS ELSA CA 15-3 test showed CVs
between approximately 4 and 9%. With the ΕΤΙ Sorin
test the CVs were well above 10%.
Inter-assay variation (tab. 2):
All four sites performed tests on the two IMx controls
and included the external control sera Lyphochek. As
expected, the CVs for the kit's internal and the external
control sera were slightly higher than the intra-assay fig-
ures, but they stayed within an acceptable range (^
Tab. 2 Imprecision testing
Method/site Control sample
IMx
low1
IMx
high1
Pool3 Lypho Lypho
infra-assay variation2 (N = 20)
IMx Site 1
Site 2
Site 3
Site 4
CIS Site 1
Site 2
ES 300
ΕΤΙ Sorin
2.2
3.4
3.9
3.0
4.2
3.0
4.5
3.2
3.4
4.3
(Π.8)
(14.2)
(23.4)
(14.0)
(10.5)
(20.0)
(13.0)
2.7
2.6
2.1
1.9
5.2
8.6
2.0
(32.2) 22.8
Inter-assay variation2 (N = 10)
3.8
2.9
18.7
5.0
1.4
11.4
IMx Site 1
Site 2
Site 3
Site 4
CIS Site 1
Site 2
ES 300
ΕΤΙ Sorin
4.0
5.1
4.1
2.9
5.5
7.7
6.3
7.1
4.2
4.5
3.8
3.5
5.7
19.1
5.3
26.9
3.6
5.1
5.0
3.9
2.1
18.8
9.4
11.3
1
 cf. table 3 for mean concentrations
2
 Coefficients of variation (C V %)
3
 Pool: Site-specific pool of sera with an average concentration of
CA 15-3 (Χ 103 U/l)
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for the IMx, but not for the CIS ELSA at site 2, or for
the ΕΤΙ Sorin test.
Lower l imit of detection
The lower limits of detection of the tests [sensitivity
(103 U/l): mean of zero standards plus 2 standard devia-
tions] claimed by the manufacturers were 0.2 X 103 U/l
(IMx), 0.9 X 103 U/l (ES 300), 0.2 Χ ΙΟ3 U/l (CIS
ELSA) and 1.0 X 103 U/l (ΕΤΙ Sorin). The results ob-
tained in the four laboratories were 0.1, 0.13, 0.07, 0.06
X 103 U/l for the IMx, 1.9 and 0.83 Χ 103 U/l for CIS
ELSA (site 1 and site 2), 0.15 Χ 103 U/l for the ES 300,
and 3.87 X 103 U/l for ΕΤΙ Sorin.
Dilut ion linearity
Figure 1 shows the dilution linearity of the individual
tests at two different concentrations levels. It should be
noted that the results shown are from four different sam-
ples and are a representation of a set of samples run in
each laboratory.
The IMx target and analysed values show the closest
agreement at levels of approximately 800 and 1300
Χ 103 U/l. In the ES 300 method a tendency to higher
values with increasing dilution is observed. Interest-
ingly, the CIS ELSA IRMA test shows good linearity at
600 Χ 103 U/l but varying results at higher concentra-
tions. The ΕΤΙ Sorin test deviated drastically from the
target values.
Comparison of analytical procedures
Table 3 summarizes the results of the CA 15-3 determin-
ations in quality control samples measured on different
days and compares these values with the assigned con-
centration ranges for CA 15-3 in these test samples. All
the test systems measured CA 15-3 in the targeted con-
centration ranges. However, the column "Miii-Max"
(tab. 3) indicates that the concentration ranges are very
narrow with the IMx but somewhat broader with the
other methods. The ΕΤΙ Sorin method in particular
shows a very broad concentration range. Interestingly, at
one site where the BioRef samples were measured by
the IMx and by the CIS ELSA, values appeared in rather
narrow ranges for IMx and closer to the assigned values
for CIS ELSA than CIS ELSA values themselves
(tab. 3).
Patient samples
Each laboratory assayed approximately 100 serum or
plasma samples simultaneously in the routine and IMx
assay. Table 4 and figures 2 to 5 show the correlation
coefficients and the regression coefficients obtained as
analysed using the Passing-Pablok method (12) over the
whole concentration ranges. These data show that even
Tab. 3 Comparison of mean values (different days) with assigned values of commercially available
control samples for all instruments
Method, site N Mean
(X 103 U/l)
Min-Max
(X 103U/i)
Assigned mean (Assigned range)
(X 103 U/l)
IMx site 1
IMx site 2
IMx site 3
IMx site 4
ES 300
ΕΤΙ Sorin
CIS ELSA site 2
IMx site 1
IMx site 2
IMx site 3
IMx site 4
ES 300
ΕΤΙ Sorin
CIS ELSA site 2
IMx
CIS ELSA
IMx
CIS ELSA
9
7
10
10
13
10
9
10
8
10
10
13
10
10
10
10
10
10
13.0
12.0
12.2
11.3
11.4
17.0
13.9
35.7
34.0
33.9
34.2
36.8
44.4
42.4
19.5
22.4
65.7
94.7
Lyphochek I
11.9-
11.3-
11.3-
10.7-
10.5-
13.4^
11.5-
Lyphochek 2
32.4-
30.4-
31.4-
32.3-
27.1-
37.1-
31.9-
13.9
12.9
13.1
12.0
12.3
27.5
20.0
36.6
36.9
37.2
36.5
41.4
52.9
61.5
BioRef 1
17.5- 20.9
18.6- 27.0
BioRef2
10.7(8.6-12.8)
13.1(9.1-17.1)
11.0(9.0-13.0)
59.3- 74.4
84.5-107.0
36.6 (29.3-43.9)
38.8(27.9-49.7)
32.0(26.0-38.0)
17.0(10.0-23.0)
68.4(40,0-95.0)
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Tab. 4 Comparison of methods, regression analyses (y
(12)(cf. figs. 2 to 5)
ax + b) by the method of Passing & Bablok
Site x-axis y-axis n a Median (min—max)
(X 103 U/l)
Comments
1
2
3
4
CIS ELSA IMx 122
98
CIS ELSA IMx 101
86
ES 300 IMx 129
105
ΕΤΙ Sorin IMx 184
57
16
20
15
13
30
30
0.950
0.998
0.980
0.931
0.952
0.975
0.945
0.984
0.963
0.871
9.852
0.988
0.969
0.782
0.758
0.837
0.762
0.666
0.620
0.733
0.577
0.678
0.845
0.654
0.666
0.358
0.601
0.064
0.219
1.374
2.814
-0.820
0.565
-2.168
-1.323
-1.453
-2.537
0.364
0.621
IMx = 28.2 (4.9-10260)
IMx = 19.9 (4.9- 248)
IMx = 28.0 (4.6-12960)
IMx = 22.5 (4.6- 245)
IMx = 3 1.3 (6.6- 3240)
IMx = 23.5 (6.6- 247)
IMx= 15.6 (4.8- 250)
IMx= 15.5 (4.8- 250)
IMx= 18.6 (8.3- 89.3)
IMx= 16.6 (5.1- 31.8)
IMx= 15.0 (6.3- 26.9)
IMx = 23.4 (9.3- 250)
IMx = 15.2 (5.5- 42.4)
IMx = 14.4 (5.0- 24.0)
he pari n plasma
heparin plasma
serum
serum
serum
serum
all patients, serum
breast cancer
lung cancer
benign breast diseases
colorectal cancer
ovarian and uterine cancer
general diseases
healthy females
though the correlation coefficients between IMx and CIS
ELSA are equal at sites 1 and 2, there is a difference in
the slopes of the regression lines (see discussion below).
The slope found at site 2 corresponds well to that found
at the other two sites where the ES 300 and the ΕΤΙ
Sorin methods were compared with the IMx. At one site
(site 4) the test results were broken down into diverse
types of non-breast cancers and benign breast lesions;
the regression coefficients and the slopes of the regres-
sion lines did not vary dramatically from the main pop-
ulation.
As demonstrated in figures 2 to 5, most samples contain
CA 15-3 in the concentration range of less than 50
X 103 U/l. Values equal to or greater than this concen-
tration tend to vary widely. Dilutions in serum with CA
15-3 concentrations > 200 Χ 103 U/l were not linear
with the ΕΤΙ Sorin method and are therefore not shown
in figure 5. The regression lines deviate from the ideal
45° in all methods using serum samples. This stands in
contrast to the comparison study using heparin plasma
samples (site 1).
Discussion
CA 15-3 measurements are widely used in the manage-
ment of breast cancer treatment and the test is very help-
ful for the early detection of recurrence of the disease.
The sensitivity of the test for indicating small changes
in tumour growth justifies automation of the method in
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Fig. 2 Comparison IMx versus CIS ELSA for serum: statistical analysis of results was
performed by the method of Passing & Bablok.
n = 122, r = 0.950, y = 0.988x + 0.358
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order to obtain test results quickly. These readily avail-
able results allow an effective adaptation of therapy to
the growth characteristics of the tumour.
Before using a new test system, it is important for a
testing laboratory to know how the new test compares
with tests already in use. In this study the automated
methods of Abbott IMx and Boehringer ES 300 were
compared. With the same study protocol, Abbott IMx
was compared with the manual methods CIS ELSA and
ΕΤΙ Sorin.
The test results of this study show that although
the original CIS ELSA test performed satisfactorily,
the automation of the method indeed improved the
performance. The two automated Systems (IMx and
ES 300) performed equally well when tested for im-
precision.
18000
2000 4000 6000 8000 10000 12000 14000
CA 15-3 (CIS ELSA RIA)[103U/I]
16000 18000
Fig. 3 Comparison IMx versus CIS ELSA for heparin plasma: statistical analysis of results
was performed by the method of Passing & Bablok.
n = 101, r = 0.998, y = 0.782x + 0.064
3500
1000 1500 2000 2500 3000 3500
CA 15-3 (BMC ES 300 EiA)[103U/IJ
Fig. 4 Comparison IMx versus BMC ES 300 for heparin plasma: statistical analysis
of results was performed by the method of Passing & Bablok
n = 129, r = 0.980, y = 0.837x + 1.374
BMC = Boehringer Mannheim Corporation
Huber et al.: CA 15-3: A multicentre evaluation of tests 83
20 60 80 100 120 140
CA 15-3 (ΕΤΙ Sorin) 11 (P U/l I
160 180 200
Fig. 5 Comparison IMx versus ET! Sorin: Statistical analysis of results was performed
by the method of Passing & Bab/ok.
n = 181, r = 0.931, y = 0.666x + 0.820
As expected and known from experience with manual
methods, inter-assay variation was slightly worse than
intra-assay variation for the same sample type (tab. 2).
In particular the intra- and inter-assay variations ob-
served with the ΕΤΙ Sorin test were unsatisfactory. Al-
though the lower limit of detection of the CA 15-3 assay
is not a criterion important to the patient, all four meth-
ods were sensitive enough and relatively close to the
sensitivities claimed by each manufacturer. The linearity
tests are of much greater importance, because clinical
experience shows that high values of the antigen are to
be expected. Therefore, the tests have to yield correct
values when samples are diluted serially. Here the auto-
mated tests performed well, even though the dilutions
had to be carried out manually. The manual tests under
investigation seem to be less reliable in this respect and
gave dilution values which were too high, reflecting the
higher imprecision of these tests (tab. 2).
Day-to-day precision was satisfactory for each test as
demonstrated in table 2. Here it is interesting to note
that CA 15-3 values obtained by the IMx system with
the BioRef quality-control sera, which is apparently pro-
duced from cell cultures, are closer to the target values
published by the manufacturer for the CIS ELSA
method than we found with the same method.
CA 15-3 is recommended as a serum marker for the
follow-up of treatment. The necessity to measure accu-
rately high values of the marker must be anticipated.
Dilution of the specimen is often necessary.
As one examines the correlation results of the IMx vs
the comparison systems under investigation (figs. 2 to
5) the discrepancies between methods became most
prominent at higher values, starting at levels between
2500 and 4000 X 103 U/l for the ES 300 and CIS ELSA
(site 1 and 2) assays. Results from the ΕΤΙ Sorin method
start to differ from those from the IMx at much lower
concentrations (60 X 103 U/l). In the latter situation se-
vere misinterpretation would occur if methods were
changed during the follow-up of disease.
Comparison of patient sample values from the IMx
method with those from its competitors shows that the
correlation between IMx and CIS ELSA is better when
measurements are performed on heparin plasma, rather
than on serum. Furthermore, the comparison between
IMx and the two other methods (ES 300 and ΕΤΙ Sorin),
also performed on serum samples, gives slopes of the
same order as those obtained with the CIS ELSA versus
IMx comparison for serum samples. These observations
point to a possible effect of heparin; the nature of this
effect is unknown, but one might speculate that heparin
possibly stabilizes the CA 15-3 molecule by binding to
it (CA 15-3 is a mucin and heparin a polyanion; heparin
is also used to purify mucin-type proteins). Whatever
the mechanism, the practical implication of our observa-
tion is that the follow-up of a patient with CA 15-3 mea-
surements should always be performed on the same type
of sample and by the same laboratory.
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